ArticleCancer chemotherapy and pharmacology2020
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.
Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management.Drug delivery and translational research · 2026Article
- Palmitoylated importin α recruits PKCε to the plasma membrane to drive breast cancer cell motility.bioRxiv : the preprint server for biology · 2026Article
- Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Case Report: Metastatic melanoma with initial ctdna decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?Frontiers in oncology · 2026Article
- Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?Current oncology reports · 2025Review
- Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts.Medical oncology (Northwood, London, England) · 2025Article
- Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma.Biomaterials research · 2025Article
- Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells.PloS one · 2025Article
- Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches.The EPMA journal · 2024Article
- Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway.Acta biochimica et biophysica Sinica · 2024Article
- Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model.ACS pharmacology & translational science · 2024Article
- ACV with/without IVM: a new talk on intestinal CDX2 and muscular CD34 and Cyclin D1 duringHelminthologia · 2024Article
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in oncology · 2024Review
- TTT (Tel2-Tti1-Tti2) Complex, the Co-Chaperone of PIKKs and a Potential Target for Cancer Chemotherapy.International journal of molecular sciences · 2023Review
- Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer.International journal of molecular sciences · 2023Review
- The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.International journal of molecular sciences · 2022Article
- Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.Life (Basel, Switzerland) · 2022Review
- Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways.Pharmacology research & perspectives · 2022Article
- Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells.International journal of medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIvermectin is an antiparasitic drug that exhibits antitumor effects in preclinical studies, and as such is currently being repositioned for cancer treatment. However, divergences exist regarding its employed doses in preclinical works. Therefore, the aim of this study was to determine whether the antitumor effects of ivermectin are observable at clinically feasible drug concentrations.
methodsTwenty-eight malignant cell lines were treated with 5 μM ivermectin. Cell viability, clonogenicity, cell cycle, cell death and pharmacological interaction with common cytotoxic drugs were assessed, as well as the consequences of its use on stem cell-enriched populations. The antitumor in vivo effects of ivermectin were also evaluated.
resultsThe breast MDA-MB-231, MDA-MB-468, and MCF-7, and the ovarian SKOV-3, were the most sensitive cancer cell lines to ivermectin. Conversely, the prostate cancer cell line DU145 was the most resistant to its use. In the most sensitive cells, ivermectin induced cell cycle arrest at G
conclusionOur results on the antitumor effects of ivermectin support its clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.